Idenix Pharmaceuticals — Investor Presentation (September 2012)
14 slides from Idenix Pharmaceuticals's investor presentation, Sep 20, 2012
Slide 1: Investor Presentation September 20, 2012
1 Investor Presentation September 20, 2012
Slide 2: Safe Harbor Statement
2 Building a Leading Antiviral Franchise Safe Harbor Statement This presentation includes forward-looking statements about Idenix and its business, including without limitation, statements regarding drug discovery, research and clinical development, regulatory approval processes and market opportuni
Slide 3: Idenix Pharmaceuticals Highlights
3 Building a Leading Antiviral Franchise Idenix Pharmaceuticals Highlights Focused on development of next-generation antiviral oral combination treatments for hepatitis C virus (HCV) infection IDX184, an HCV nucleotide polymerase inhibitor, in phase IIb trials Interim SVR4 and 12-week cEVR data demo
Slide 4: The HCV Treatment Paradigm is Evolving Rapidly
Convenient Once- or twice-daily Low dosage Fixed-dose Ease of Administration ^ 12 weeks duration Simple stopping rules All Oral PegIFN-free RBV still a question Potent >80% SVR Nulls, relapsers, cirrhotics High barrier to resistance Safe Low toxicity High tolerability Minimal AEs Pan-genotypic Can b
Slide 5: HCV Pipeline Overview
HCV Pipeline Overview 5 Building a Leading Antiviral Franchise Characteristics IDX184* IDX719 IDX19368** Drug Class Nucleotide Inhibitor NS5A Inhibitor Nucleotide Inhibitor Phase IIb Ib/IIa Preclinical Genotype coverage Pan-genotypic Pan-genotypic Pan-genotypic Barrier to resistance High Low High Ef
Slide 6: FDA placed IDX184 on partial clinical hold and IDX19368 on clinical hold
6 Building a Leading Antiviral Franchise In August 2012, FDA placed IDX184 on partial clinical hold and IDX19368 on clinical hold due to serious cardiac-related adverse events seen with BMS-094 (formerly INX-189) Idenix is working with FDA and BMS to resolve the clinical holds Idenix received formal
Slide 7: No evidence to date of cardiotoxicity in patients dosed with IDX184
7 Building a Leading Antiviral Franchise There has been no evidence to date of cardiotoxicity in patients dosed with IDX184 with PegIFN/RBV beyond that seen with PegIFN/RBV alone No patients have been exposed to IDX19368 The three compounds share the same active metabolite (2'-methyl G) however, we
Slide 8: IDX184: Phase IIb 12-Week PegIFN/RBV Study Overview
8 Building a Leading Antiviral Franchise Phase IIb study status In July 2012, DSMB confirmed no safety or efficacy concerns; side effect profile remains consistent with known safety profile of PegIFN/RBV alone No patients are receiving IDX184. Patients currently on PegIFN/RBV extension IDX184 was pl
Slide 9: IDX184 Interim Antiviral Activity and Safety Summary - First Cohort
Safety: Safety observed to date consistent with known safety profile of PegIFN/RBV alone IDX184* Interim Antiviral Activity and Safety Summary - First Cohort Phase IIb 12-Week PegIFN/RBV Study 9 Building a Leading Antiviral Franchise n Median Time to <25 IU/mL 50 mg IDX184 + Peg/RBV 16 22 days 100 m
Slide 10: Novel Nucleotide Prodrug Discovery Program: IDX19368
Novel Nucleotide Prodrug Discovery Program IDX19368: Selected as First Candidate Lead nucleotide inhibitor candidate, IDX19368, selected from a prodrug series of ~350 compounds IDX19368 is a 2'Me-ribonucleoside (2'MeNuc) prodrug Potent activity in the replicon system in vitro Good stability in biolo
Slide 11: IDX719: NS5A Inhibitor Strong Preclinical Profile
11 Building a Leading Antiviral Franchise IDX719: NS5A Inhibitor Strong Preclinical Profile EC50 versus HCV replicon (pM) Potent broad genotypic activity across multiple genotypes with high selectivity indices in vitro (2-24 pM activity overall) Clean preclinical safety profile to date Low potential
Slide 12: IDX719: Potent and Pan-genotypic in 3-Day Proof-of-Concept Study
IDX719: Phase I/II Study Potent and Pan-genotypic in 3-Day Proof-of-Concept Study 12 Building a Leading Antiviral Franchise Dose Mean Maximum Viral Load Reduction Mean Maximum Viral Load Reduction Mean Maximum Viral Load Reduction Mean Maximum Viral Load Reduction GT1 n=28 GT2 n=8 GT3 n=8 GT4 n=7 25
Slide 13: Changes to Collaboration with Novartis
Changes to Collaboration with Novartis Key Terms of Termination and Revised Relationship Agreement 13 Building a Leading Antiviral Franchise Pipeline rights: Idenix regained rights to our current or future drug candidates in any therapeutic area Idenix will pay royalties based on WW product sales of
Slide 14: Financial Highlights
14 Building a Leading Antiviral Franchise Financial Highlights $ Millions (unaudited) FYE 2011 Q1 2012 Q2 2012 Total Revenue $7.0 $35.6 $1.4 R&D Expense $41.3 $18.6 $20.5 G&A Expense $16.7 $4.8 $5.9 Net Loss $(52.0) $11.4 $(25.4) As of June 30, 2012 As of June 30, 2012 Cash Balance $79.3* $ Millions
Idenix Pharmaceuticals — Investor Presentation (September 2012) on 6ix